George Matcham
Directeur/Membre du Conseil chez INSTIL BIO, INC.
Fortune : 419 269 $ au 31/05/2024
Postes actifs de George Matcham
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INSTIL BIO, INC. | Directeur/Membre du Conseil | 01/09/2018 | - |
| Independent Dir/Board Member | 01/09/2018 | - |
Historique de carrière de George Matcham
Anciens postes connus de George Matcham
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Directeur/Membre du Conseil | 05/07/2021 | 03/08/2023 |
| CELGENE | Corporate Officer/Principal | 01/05/2013 | 01/06/2018 |
Celgene Cellular Therapeutics
 Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Directeur des opérations | - | - |
Formation de George Matcham
| University of Cardiff | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Royaume-Uni | 3 |
| Australie | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
| Chief Operating Officer | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INSTIL BIO, INC. | Health Technology |
| CHIMERIC THERAPEUTICS LIMITED | Health Technology |
| Entreprise privées | 2 |
|---|---|
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Bourse
- Insiders
- George Matcham
- Expérience
